WASHINGTON, D.C., May 3, 2016 – The Alliance for Regenerative Medicine (ARM) today announced the release of its quarterly data report, offering an in-depth look at cell therapy, gene therapy and broader global regenerative medicine sector trends and metrics in the first quarter of 2016.
Using information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from more than 685 leading cell therapy, gene therapy and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key data events and ARM’s current legislative and regulatory priorities.
The Q1 2016 data report includes sections featuring ARM member organization and key stakeholder perspectives, highlighting important focus areas for the sector:
• The importance and role of patient outreach and education in our sector, commentary from Audentes Therapeutics; bluebird bio; Friedreich’s Ataxia Research Alliance; GSK; and Voyager Therapeutics.
• Industrialization and manufacturing requirements to advance the sector, commentary from CCRM; Cell and Gene Therapy Catapult; GE Healthcare; Invetech; Lonza; and PharmaCell.
“Despite the downturn in the global financial markets, the gene and cellular therapies and regenerative medicine sector had several noteworthy financings, along with numerous positive data and regulatory developments,” said Morrie Ruffin, ARM’s managing director. “As 2016 moves forward, our priorities are on continuing to move this sector forward, clinically, financially and legislatively.”
Highlighted findings from the Q1 2016 data report include:
• Globally, companies active in gene and cellular therapies and other regenerative medicines raised more than $1.2 billion in Q1. The report also includes data broken out by technology and financing type.
• There were 669 clinical trials underway worldwide at the close of the first quarter of 2016. The report includes figures on clinical trials by phase and indication.
• Areas of regulatory and legislative focus moving in to Q2 2016, including reimbursement policies; ARM’s Standards Coordinating Body initiative; international regulatory convergence; streamlining and optimizing drug development and review; PDUFA reauthorization; and more.
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers and clinical data events.
The report is available online here. For more information, please visit alliancerm.org or contact Lyndsey Scull at email@example.com.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 240 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.